Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2011 | 12-2010 | 09-2010 | 06-2010 | 03-2010 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,835,978 | 907,879 | 1,022,993 | 1,482,639 | 936,880 |
| Marketable Securities | 1,175,321 | 1,190,789 | 1,284,538 | 518,286 | 715,308 |
| Receivables | 1,801,212 | 1,621,966 | 1,670,405 | 1,482,900 | 1,491,332 |
| Inventories | 1,304,457 | 1,203,809 | 1,273,389 | 1,356,606 | 1,223,945 |
| Income taxes - deferred | 277,835 | 279,339 | 310,316 | 288,642 | 283,585 |
| Other current assets | 96,081 | 116,244 | 111,651 | 243,550 | 139,880 |
| TOTAL | $6,851,132 | $5,708,082 | $6,031,947 | $5,709,014 | $5,124,228 |
| Non-Current Assets | |||||
| PPE Net | 703,794 | 701,235 | 692,032 | 695,043 | 695,601 |
| Investments And Advances | 3,344,999 | 3,219,403 | 2,744,150 | 2,216,610 | 2,967,727 |
| Intangibles | 1,629,971 | 1,425,592 | 1,576,573 | 1,494,813 | 1,509,794 |
| Other Non-Current Assets | 457,458 | 538,318 | 410,889 | 381,228 | 398,648 |
| TOTAL | $6,136,222 | $5,884,548 | $5,423,644 | $4,787,694 | $5,571,770 |
| Total Assets | $12,987,350 | $11,592,630 | $11,455,590 | $10,496,710 | $10,696,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 653,093 | N/A | N/A | 1,124,230 | 7,088 |
| Accounts payable and accrued liabilities | 981,631 | 803,025 | 950,813 | 1,066,433 | 949,084 |
| Accrued Expenses | 467,638 | 472,650 | 428,642 | 400,613 | 381,847 |
| TOTAL | $2,768,765 | $2,464,950 | $2,590,108 | $3,105,723 | $1,887,651 |
| Non-Current Liabilities | |||||
| Long Term Debt | 3,899,928 | 2,865,974 | 47,760 | 23,050 | 27,290 |
| Deferred Revenues | 97,373 | 103,175 | 95,794 | 116,360 | 122,240 |
| Other Non-Current Liabilities | 116,863 | 110,079 | 2,902,218 | 631,343 | 1,239,703 |
| TOTAL | $4,043,228 | $3,005,843 | $2,986,711 | $690,985 | $1,305,675 |
| Total Liabilities | $6,811,993 | $5,470,793 | $5,576,819 | $3,796,708 | $3,193,326 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,574,109 | 1,590,529 | 1,623,735 | 1,677,265 | 1,779,830 |
| Common Shares | 791 | 802 | 815 | 860 | 902 |
| Retained earnings | 1,320,335 | 1,183,730 | 1,122,030 | 1,831,381 | 2,688,679 |
| Other shareholders' equity | 127,926 | 289,019 | 179,943 | 327,129 | 244,149 |
| TOTAL | $6,175,361 | $6,121,837 | $5,878,772 | $6,700,000 | $7,502,672 |
| Total Liabilities And Equity | $12,987,354 | $11,592,630 | $11,455,591 | $10,496,708 | $10,695,998 |